HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

AbstractBACKGROUND:
Few biomarkers of ovarian cancer prognosis have been established, partly because subtype-specific associations might be obscured in studies combining all histopathological subtypes. We examined whether tumour expression of the progesterone receptor (PR) and oestrogen receptor (ER) was associated with subtype-specific survival.
METHODS:
12 studies participating in the Ovarian Tumor Tissue Analysis consortium contributed tissue microarray sections and clinical data to our study. Participants included in our analysis had been diagnosed with invasive serous, mucinous, endometrioid, or clear-cell carcinomas of the ovary. For a patient to be eligible, tissue microarrays, clinical follow-up data, age at diagnosis, and tumour grade and stage had to be available. Clinical data were obtained from medical records, cancer registries, death certificates, pathology reports, and review of histological slides. PR and ER statuses were assessed by central immunohistochemistry analysis done by masked pathologists. PR and ER staining was defined as negative (<1% tumour cell nuclei), weak (1 to <50%), or strong (≥50%). Associations with disease-specific survival were assessed.
FINDINGS:
2933 women with invasive epithelial ovarian cancer were included: 1742 with high-grade serous carcinoma, 110 with low-grade serous carcinoma, 207 with mucinous carcinoma, 484 with endometrioid carcinoma, and 390 with clear-cell carcinoma. PR expression was associated with improved disease-specific survival in endometrioid carcinoma (log-rank p<0·0001) and high-grade serous carcinoma (log-rank p=0·0006), and ER expression was associated with improved disease-specific survival in endometrioid carcinoma (log-rank p<0·0001). We recorded no significant associations for mucinous, clear-cell, or low-grade serous carcinoma. Positive hormone-receptor expression (weak or strong staining for PR or ER, or both) was associated with significantly improved disease-specific survival in endometrioid carcinoma compared with negative hormone-receptor expression, independent of study site, age, stage, and grade (hazard ratio 0·33, 95% CI 0·21-0·51; p<0·0001). Strong PR expression was independently associated with improved disease-specific survival in high-grade serous carcinoma (0·71, 0·55-0·91; p=0·0080), but weak PR expression was not (1·02, 0·89-1·18; p=0·74).
INTERPRETATION:
PR and ER are prognostic biomarkers for endometrioid and high-grade serous ovarian cancers. Clinical trials, stratified by subtype and biomarker status, are needed to establish whether hormone-receptor status predicts response to endocrine treatment, and whether it could guide personalised treatment for ovarian cancer.
FUNDING:
Carraresi Foundation and others.
AuthorsWeiva Sieh, Martin Köbel, Teri A Longacre, David D Bowtell, Anna deFazio, Marc T Goodman, Estrid Høgdall, Suha Deen, Nicolas Wentzensen, Kirsten B Moysich, James D Brenton, Blaise A Clarke, Usha Menon, C Blake Gilks, Andre Kim, Jason Madore, Sian Fereday, Joshy George, Laura Galletta, Galina Lurie, Lynne R Wilkens, Michael E Carney, Pamela J Thompson, Rayna K Matsuno, Susanne Krüger Kjær, Allan Jensen, Claus Høgdall, Kimberly R Kalli, Brooke L Fridley, Gary L Keeney, Robert A Vierkant, Julie M Cunningham, Louise A Brinton, Hannah P Yang, Mark E Sherman, Montserrat García-Closas, Jolanta Lissowska, Kunle Odunsi, Carl Morrison, Shashikant Lele, Wiam Bshara, Lara Sucheston, Mercedes Jimenez-Linan, Kristy Driver, Jennifer Alsop, Marie Mack, Valerie McGuire, Joseph H Rothstein, Barry P Rosen, Marcus Q Bernardini, Helen Mackay, Amit Oza, Eva L Wozniak, Elizabeth Benjamin, Aleksandra Gentry-Maharaj, Simon A Gayther, Anna V Tinker, Leah M Prentice, Christine Chow, Michael S Anglesio, Sharon E Johnatty, Georgia Chenevix-Trench, Alice S Whittemore, Paul D P Pharoah, Ellen L Goode, David G Huntsman, Susan J Ramus
JournalThe Lancet. Oncology (Lancet Oncol) Vol. 14 Issue 9 Pg. 853-62 (Aug 2013) ISSN: 1474-5488 [Electronic] England
PMID23845225 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2013 Elsevier Ltd. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • Receptors, Estrogen
  • Receptors, Progesterone
Topics
  • Adenocarcinoma, Clear Cell (metabolism, mortality, pathology)
  • Adenocarcinoma, Mucinous (metabolism, mortality, pathology)
  • Biomarkers, Tumor (metabolism)
  • Carcinoma, Endometrioid (metabolism, mortality, pathology)
  • Case-Control Studies
  • Cystadenocarcinoma, Serous (metabolism, mortality, pathology)
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoenzyme Techniques
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Ovarian Neoplasms (metabolism, mortality, pathology)
  • Ovary (metabolism, pathology)
  • Prognosis
  • Receptors, Estrogen (metabolism)
  • Receptors, Progesterone (metabolism)
  • Survival Rate
  • Tissue Array Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: